Sensei biotherapeutics reports second quarter 2021 results and highlights recent in vivo data from sns-vista program

- company announced first set of ph-sensitive anti-vista antibodies showing significant in vivo anti-tumor activity in combination with pd-1 blockade in a human vista knock-in mouse model –

SNSE Ratings Summary

SNSE Quant Ranking